Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
793 Views
Viva Biotech (维亚生物) Post-IPO: SELL the Overvalued Incubator
Viva Biotech's IPO was priced at the top end with a very substantial oversubscription. We have highlighted in our earlier note that Viva Biotech's...
659 Views
Frontage Holdings IPO Preview: An Uncertain Transition
Frontage Laboratories Inc (1000371Z HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347...
673 Views
Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range
Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...
670 Views
Viva Biotech (维亚生物) IPO: Valuation Rich Even at Low End
Viva Biotech launched book building today to raise up to USD 194 million via its Hong Kong IPO. In our previous insights, we have discussed the...
657 Views